Literature DB >> 32371073

Interrater Reliability in Toxicity Identification: Limitations of Current Standards.

Andrew T Fairchild1, Jarred P Tanksley1, Jessica D Tenenbaum2, Manisha Palta1, Julian C Hong3.   

Abstract

PURPOSE: The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 is the standard for oncology toxicity encoding and grading, despite limited validation. We assessed interrater reliability (IRR) in multireviewer toxicity identification. METHODS AND MATERIALS: Two reviewers independently reviewed 100 randomly selected notes for weekly on-treatment visits during radiation therapy from the electronic health record. Discrepancies were adjudicated by a third reviewer for consensus. Term harmonization was performed to account for overlapping symptoms in CTCAE. IRR was assessed based on unweighted and weighted Cohen's kappa coefficients.
RESULTS: Between reviewers, the unweighted kappa was 0.68 (95% confidence interval, 0.65-0.71) and the weighted kappa was 0.59 (0.22-1.00). IRR was consistent between symptoms noted as present or absent with a kappa of 0.6 (0.66-0.71) and 0.6 (0.65-0.69), respectively.
CONCLUSIONS: Significant discordance suggests toxicity identification, particularly retrospectively, is a complex and error-prone task. Strategies to minimize IRR, including training and simplification of the CTCAE criteria, should be considered in trial design and future terminologies.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID: 32371073     DOI: 10.1016/j.ijrobp.2020.04.040

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

1.  Deep Learning for Cancer Symptoms Monitoring on the Basis of Electronic Health Record Unstructured Clinical Notes.

Authors:  Charlotta Lindvall; Chih-Ying Deng; Nicole D Agaronnik; Anne Kwok; Soujanya Samineni; Renato Umeton; Warren Mackie-Jenkins; Kenneth L Kehl; James A Tulsky; Andrea C Enzinger
Journal:  JCO Clin Cancer Inform       Date:  2022-06

2.  Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients.

Authors:  S K B Spohn; S Adebahr; M Huber; C Jenkner; R Wiehle; B Nagavci; C Schmucker; E G Carl; R C Chen; W A Weber; M Mix; A Rühle; T Sprave; N H Nicolay; C Gratzke; M Benndorf; T Wiegel; J Weis; D Baltas; A L Grosu; C Zamboglou
Journal:  BMC Cancer       Date:  2022-03-28       Impact factor: 4.430

3.  Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification.

Authors:  Sarah Iglseder; Martha Nowosielski; Gabriel Bsteh; Armin Muigg; Johanna Heugenhauser; Elke Mayer; Astrid Grams; Günther Stockhammer; Meinhard Nevinny-Stickel
Journal:  Strahlenther Onkol       Date:  2022-03-10       Impact factor: 4.033

4.  Efficacy and safety analysis of dexamethasone-lipiodol emulsion in prevention of post-embolization syndrome after TACE: a retrospective analysis.

Authors:  Haohao Lu; Chuansheng Zheng; Bin Liang; Bin Xiong
Journal:  BMC Gastroenterol       Date:  2021-06-11       Impact factor: 3.067

5.  Natural language processing for abstraction of cancer treatment toxicities: accuracy versus human experts.

Authors:  Julian C Hong; Andrew T Fairchild; Jarred P Tanksley; Manisha Palta; Jessica D Tenenbaum
Journal:  JAMIA Open       Date:  2020-12-05

6.  Natural Language Processing to Identify Advance Care Planning Documentation in a Multisite Pragmatic Clinical Trial.

Authors:  Charlotta Lindvall; Chih-Ying Deng; Edward Moseley; Nicole Agaronnik; Areej El-Jawahri; Michael K Paasche-Orlow; Joshua R Lakin; Angelo Volandes; The Acp-Peace Investigators James A Tulsky
Journal:  J Pain Symptom Manage       Date:  2021-07-14       Impact factor: 5.576

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.